Effects of 6 months intensive vasodilating treatment on vascular resistance and coronary flow reserve in hypertensive patients - VASOMORE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-017831-16-DK

Enrollment

100

Registered

2010-07-06

Start date

2010-07-15

Completion date

Unknown

Last updated

2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension and changes in the vasculature related to high blood pressure. MedDRA version: 12.1 Level: LLT Classification code 10015488 Term: Essential hypertension MedDRA version: 12.1 Level: LLT Classification code 10015489 Term: Essential hypertension, benign MedDRA version: 12.1 Level: LLT Classification code 10015491 Term: Essential hypertension, unspecified MedDRA version: 12.1 Level: LLT Classification code 10020772 Term: Hypertension MedDRA version: 12.1 Level: LLT Classi

Interventions

Trade Name: Amlodpin Product Name: Amlodipine Product Code: 21391 Pharmaceutical Form: Tablet INN or Proposed INN: amlodipine besilate CAS Number: 111470-99-6 Concentration unit: mg milligram(s) Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Alder [25 – 80] år. -Igangværende stabil antihypertensiv behandling gennem mindst 3 måneder. Blodtryk =120/75 på behandlingen. -Ejection fraction (bestemt ved biplanemetri med ekkokardiografi) over 45 % ved inklusion Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Blodtryk = 160/100 ved inklusion -Graviditet, laktation eller mangelfuld antikonception hos menstruerende kvinder - Verificeret sekundær hypertension -Andre sygdomme: betydende hjerteklapsygdom, leversygdom, nyresygdom, diabetes, svær neurologisk sygdom, betydende psykisk sygdom, eller noncompliant personlighed i øvrigt. -Fastende blodsukker > 6,9 mmol/l. -Elektrolytforstyrrelser i stabil tilstand. -Forhøjet s-creatinin > 100 mikromol/l -Klinisk betydende leverpåvirkning. -Makroskopisk proteinuri eller hæmaturi ved fravær af nitrit (U-stix). -BMI > 35 kg/m². -Allergi overfor projektmedicin. - Antihypertensiv behandling med kombineret calcium kanal blokker + ACE-hæmmer

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the effect of vasodilatation on the coronary perfusion in patients with essential hypertension;Secondary Objective: To investigate the effect of vasodilatation on minimum forearm resistance, left ventricular mass, systolic and diastolic function;Primary end point(s): Primært endepunkt: CFR, coronar og underarms minimums modstand	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026